PALVELLA THERAPEUTICS INC
PVLA
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Palvella Therapeutics is a clinical-stage biopharmaceutical company whose lead drug candidate, QTORIN™ rapamycin, is being developed for rare skin diseases. The development of such pharmaceutical products typically requires animal testing to meet regulatory requirements for safety and efficacy prior to human trials. As a company advancing drug candidates through the clinical pipeline, Palvella Therapeutics relies on animal models as part of its research and development process. This business model inherently involves the commercial exploitation of animals for biomedical testing, which falls under the animal_exploitation exclusion category. The company's receipt of a grant from the FDA Office of Orphan Products Development further indicates its progression along a development pathway that necessitates animal data.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.